D-I03 manufacturers
- D-I03
-
- $31.00 / 1mg
-
2026-03-13
- CAS:688342-78-1
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
- D-I03
-
- $31.00 / 1mg
-
2026-03-13
- CAS:688342-78-1
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
|
| Product Name: | D-I03 | | Synonyms: | D-I03
(D103);D-I03;Thiourea, N-[2-(diethylamino)ethyl]-N'-[2-(4-ethyl-1-piperazinyl)-4-methyl-6-quinolinyl]-;1-(2-(Diethylamino)ethyl)-3-(2-(4-ethylpiperazin-1-yl)-4-methylquinolin-6-yl)thiourea;D-I03, 10 mM in DMSO | | CAS: | 688342-78-1 | | MF: | C23H36N6S | | MW: | 428.64 | | EINECS: | | | Product Categories: | | | Mol File: | 688342-78-1.mol |  |
| | D-I03 Chemical Properties |
| Boiling point | 582.0±60.0 °C(Predicted) | | density | 1.147±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: ≥ 100 mg/mL (233.30 mM) | | form | Solid | | pka | 12.00±0.70(Predicted) | | color | Off-white to light yellow | | InChI | 1S/C23H36N6S/c1-5-27(6-2)11-10-24-23(30)25-19-8-9-21-20(17-19)18(4)16-22(26-21)29-14-12-28(7-3)13-15-29/h8-9,16-17H,5-7,10-15H2,1-4H3,(H2,24,25,30) | | InChIKey | UXDGHRWOHOPKIL-UHFFFAOYSA-N | | SMILES | S=C(NCCN(CC)CC)NC1=CC2=C(C=C1)N=C(N3CCN(CC)CC3)C=C2C |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | D-I03 Usage And Synthesis |
| Uses | D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 μM. D-I03 specifically inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation with IC50s of 5 μM and 8 μM, respectively. D-I03 suppresses growth of BRCA1- and BRCA2-deficient cells and inhibits formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin[1][2]. | | Biological Activity | D-I03 is a selective inhibitor of RAD52 with a corresponding Kd value of 25.8 μM. D-I03 inhibits ssDNA annealing via RAD52 and D-loop formation with IC50 values of 5 μM and 8 μM, respectively. | | in vitro | D-I03 (0-10 μM; on days 1 and 3; Capan-1 and UWB1.289 cells) treatment preferentially suppressed the growth of Capan-1 and UWB1.289 cells in a concentration-dependent manner .
D-I03 inhibits RAD52 foci formation induced by cisplatin in BCR-ABL1-positive BRCA1-deficient 32Dcl3 murine hematopoietic cell line that expresses GFP-RAD52. In the presence of D-I03 (2.5 μM), the fraction of cells with RAD52 foci is decreased, from 38.7% to 171%; at the same time, the fraction of Cisplatin-treated cells without foci is increased from 48.4% to 71.9%. D-I03 does not effect on RAD51 foci induced by Cisplatin. Also, D-I03 alone induce neither RAD51 foci nor RAD52 foci (in BRCA1-deficient cells) indicating low genotoxicity of D-I03. Cell Proliferation Assay < tr> | Cell Line: | Capan-1 (BRCA2 ) and UWB1 .289 (BRCA1 + ) cells | | Concentration: | 0 μM, 2.5 μM, 5 μM, or 10 μM | | Incubation Time: | On days 1 and 3 | td> | Result: | Preferentially suppressed the growth of Capan-1 and UWB1.289 cells. | < /tr> | | in vivo | D-I03 (50 mg/kg/day; intraperitoneal injection; daily; for 7 days; nu/nu mice) treatment reduces BRCA1-deficient MDA-MB-436 tumor growth . Talazoparib puls D-I03 does not affect the growth of BRCA1-proficient tumors and does not exert any significant toxicity against normal tissues and organs.
Pharmacokinetic and toxicity studies indicate that maximal tolerated dose of D-I03 is ≥50 mg /kg, and t 1/2 is 23.4 hours, resulting in >1 μM maximal concentration in peripheral blood. < div class="cpd-mod-vv"> | Animal Model: | Nu/nu mice injected with BRCA1-deficient MDA-MB-436 cells | | Dosage: | 50 mg/kg/day | | Administration: | Intraperitoneal injection; daily; for 7 days | | Result: | Reduced BRCA1-deficient MDA-MB-436 tumor growth. | | | target | | Target | Value | RAD52
(Cell-free assay) | 25.8 μM(Ki) |
| | References | [1] Huang F, et al. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Res. 2016 May 19;44(9):4189-99. DOI:10.1093/nar/gkw087
[2] Hengel SR, et al. Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy. Cell Chem Biol. 2017 Sep 21;24(9):1101-1119. DOI:10.1016/j.chembiol.2017.08.027
[3] Sullivan-Reed K, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136. DOI:10.1016/j.celrep.2018.05.034 |
| | D-I03 Preparation Products And Raw materials |
|